Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
The DOI matches its Crossref record; 74 of the 75 references it cites were found in a registry or an index.
Abstract
Maintaining research and development (R&D) productivity at a sustainable level is one of the main challenges currently facing the pharmaceutical industry. In this article, we discuss the results of a comprehensive longitudinal review of AstraZeneca's small-molecule drug projects from 2005 to 2010. The analysis allowed us to establish a framework based on the five most important technical determinants of project success and pipeline quality, which we describe as the five 'R's: the right target, the right patient, the right tissue, the right safety and the right commercial potential. A sixth factor - the right culture - is also crucial in encouraging effective decision-making based on these technical determinants. AstraZeneca is currently applying this framework to guide its R&D teams, and although it is too early to demonstrate whether this has improved the company's R&D productivity, we present our data and analysis here in the hope that it may assist the industry overall in addressing this key challenge.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“There is accumulating evidence that the success of candidate drugs is greatly enhanced if the drug target is independently confirmed by human genetic data.16, 17”
From Early Neurological Change After Ischemic Stroke Is Associated With 90-Day Outcome (2021) · cites this paper as [16]
In the citing paper
“Currently, techniques like structural magnetic resonance imaging (MRI), and molecular imaging of deposited Aβ and tau proteins using positron emission tomography (PET), are highly accurate in detecting the presence of pathophysiological and neuropathological changes of AD and are used in the drug development [10, 11].”
From Integrated analysis of ultra-deep proteomes in cortex, cerebrospinal fluid and serum reveals a mitochondrial signature in Alzheimer’s disease (2020) · cites this paper as [10]
In the citing paper
“In the past, other medical fields tried to address similar problems by increasing the volume of trials.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“In reality, research and development costs increased while the number of drugs approved remained static106,107.”
From Drug development for neurodevelopmental disorders: lessons learned from fragile X syndrome (2018) · cites this paper as [106]
In the citing paper
“Early initiation of PK/PD assessment facilitates understanding of the biology by validating and confirming target engagement.50”
From Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development (2018) · cites this paper as [50]
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 4×
“Although clinical validation was not confirmed in the Phase IIa studies, retrospective analysis suggested that AZD1981 showed limited efficacy in an atopic/allergic asthma population selected by a positive skin prick test.”
BackgroundInfluentialInhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
How to improve R&D productivity: the pharmaceutical industry's grand challenge
Paul, S. M., Mytelka, D. S., Dunwiddie, C. T., Persinger, C. C., Munos, B. H., Lindborg, S. R., & Schacht, A. L. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3078 · Cited by 3,566
Genomic responses in mouse models poorly mimic human inflammatory diseases
Seok, J., Warren, H. S., Cuenca, A. G., Mindrinos, M. N., Baker, H. V., Xu, W., Richards, D. R., McDonald-Smith, G. P., Gao, H., Hennessy, L., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1222878110 · Cited by 3,005 · cited 1×
“29 (13) Dose limited by compound characteristics or tissue exposure not established”
BackgroundPavord, I. D., Korn, S., Howarth, P., Bleecker, E. R., Buhl, R., Keene, O. N., Ortega, H., & Chanez, P. (2012) · The Lancet · doi:10.1016/s0140-6736(12)60988-x · Cited by 2,221
Diagnosing the decline in pharmaceutical R&D efficiency
Scannell, J. W., Blanckley, A., Boldon, H., & Warrington, B. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3681 · Cited by 1,981 · cited 1×
“11 (5) Evidence from previous phase not robust enough”
BackgroundLeckie, M. J., Brinke, A. T., Khan, J., Diamant, Z., O'Connor, B. J., Walls, C. M., Mathur, A. K., Cowley, H. C., Chung, K. F., Djukanovic, R., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)03496-6 · Cited by 1,814
Lebrikizumab Treatment in Adults with Asthma
Corren, J., Lemanske, R. F., Hanania, N. A., Korenblat, P. E., Parsey, M. V., Arron, J. R., Harris, J. M., Scheerens, H., Wu, L. C., Su, Z., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1106469 · Cited by 1,514
Research works printed but not linked: 3
- Herper, M. The truly staggering cost of inventing new drugs. Forbes [online] , (10 Feb 2012).
- Redfern, W. et al. Impact and frequency of different toxicities throughout the pharmaceutical life cycle. The Toxicologist 114, 231 (2010).
- Quirk, M. et al. Abstract P-09-045. Effects of low-trapping NMDA channel blocker AZD6765 on gamma-band EEG and psychotomimetic liability: a comparison to ketamine in freely behaving rats. Int. J. Neuropsychopharmacol. 15 (Suppl. S1), 153 (2012).
Cited by
Items 301–400 of 1,000
Li, Y., Chen, J., Bolinger, A. A., Chen, H., Liu, Z., Cong, Y., Brasier, A. R., Pinchuk, I. V., Tian, B., & Zhou, J. (2021) · Inflammatory Bowel Diseases · doi:10.1093/ibd/izab190 · Cited by 47
David, F., Davis, A. M., Gossing, M., Hayes, M. A., Romero, E., Scott, L. H., & Wigglesworth, M. J. (2021) · SLAS DISCOVERY · doi:10.1177/24725552211000669 · Cited by 50
A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life
Souders, C. A., Nelson, S. C., Wang, Y., Crowley, A. R., Klempner, M. S., & Thomas, W. (2015) · mAbs · doi:10.1080/19420862.2015.1054585 · Cited by 44
“PK properties are often critical to the success of a therapeutic, and recent reports have suggested »15% of Phase 1 clinical studies fail due to inadequate PK or pharmacodynamics properties.(70) This is especially true for antibodies, where typically longer halflives are desired for therapeutics to decrease dosing fre…”
BackgroundUnderstanding Cytotoxicity and Cytostaticity in a High-Throughput Screening Collection
Mervin, L., Cao, Q., Barrett, I. P., Firth, M. A., Murray, D., McWilliams, L. J., Haddrick, M., Wigglesworth, M. J., Engkvist, O., & Bender, A. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00538 · Cited by 52
Zinnhardt, B., Wiesmann, M., Honold, L., Barca, C., Schäfers, M. A., Kiliaan, A. J., & Jacobs, A. H. (2018) · Theranostics · doi:10.7150/thno.24128 · Cited by 50
“As target availability and resulting patient stratification is a key determinant of sample sizes in clinical trials, molecular imaging will provide important information to determine sample sizes and to define inclusion and exclusion information earlier than standard clinical assessments and at the same time increase…”
BackgroundNanoparticle delivery systems to combat drug resistance in ovarian cancer
Miller, E., Samec, T., & Alexander-Bryant, A. A. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102309 · Cited by 51
Paliwal, S., de Giorgio, A., Neil, D., Michel, J.-B., & Lacoste, A. M. (2020) · Scientific Reports · doi:10.1038/s41598-020-74922-z · Cited by 45
Saleh, M. A. A., Loo, C. F., Elassaiss‐Schaap, J., & de Lange, E. C. M. (2021) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-021-09768-7 · Cited by 44
Large-scale Pan-cancer Cell Line Screening Identifies Actionable and Effective Drug Combinations
Cheraghchi-Bashi-Astaneh, A., Coker, E. A., Bulusu, K. C., Jaaks, P., Crafter, C., Lightfoot, H. W., Milo, M., McCarten, K., Jenkins, D. F., van der Meer, D. J., et al. (2024) · Cancer Discovery · doi:10.1158/2159-8290.cd-23-0388 · Cited by 48
“Employment of several criteria into portfolio decisions has resulted in higher success rate during discovery and development of novel drugs (4,5), including considerations of the target (efficacy), safety, patient population, exposure, and commercial opportunity.”
Doornbos, M. L. J., Pérez‐Benito, L., Tresadern, G., Mulder‐Krieger, T., Biesmans, I., Trabanco, A. A., Cid, J. M., Lavreysen, H., IJzerman, A. P., & Heitman, L. H. (2015) · British Journal of Pharmacology · doi:10.1111/bph.13390 · Cited by 43
“Development of AZD8529 (described in patent WO2008150233, Ball et al., 2012) from AstraZeneca was discontinued after a phase 2a study in schizophrenic patients due to a lack of efficacy (Cook et al., 2014).”
BackgroundPerspectives on Drug Repurposing
Schcolnik‐Cabrera, A., Juárez-López, D., & Dueñas‐González, A. (2020) · Current Medicinal Chemistry · doi:10.2174/0929867327666200831141337 · Cited by 47
Hodgkinson, T., Tsimbouri, P. M., Llopis-Hernández, V., Campsie, P., Scurr, D. J., Childs, P. G., Phillips, D. J., Donnelly, S., Wells, J. A., O’Brien, F. J., et al. (2021) · Science Advances · doi:10.1126/sciadv.abb7921 · Cited by 46
Enhanced Characterization of Contractility in Cardiomyocytes During Early Drug Safety Assessment
Butler, L., Cros, C., Oldman, K. L., Harmer, A., Pointon, A., Pollard, C. E., & Abi‐Gerges, N. (2015) · Toxicological Sciences · doi:10.1093/toxsci/kfv062 · Cited by 49
Aligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Bassan, A., Alves, V. M., Amberg, A., Anger, L. T., Auerbach, S. S., Beilke, L. D., Bender, A., Cronin, M., Cross, K. P., Hsieh, J., et al. (2021) · Computational Toxicology · doi:10.1016/j.comtox.2021.100187 · Cited by 52
Drug discovery using induced pluripotent stem cell models of neurodegenerative and ocular diseases
Hung, S. S. C., Khan, S., Lo, C. Y.-W., Hewitt, A. W., & Wong, R. C. B. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.026 · Cited by 49
Genetics in ankylosing spondylitis – Current state of the art and translation into clinical outcomes
Brown, M. A., & Wordsworth, B. P. (2017) · Best Practice & Research Clinical Rheumatology · doi:10.1016/j.berh.2018.09.005 · Cited by 45
“Best Practice and Research in Clinical Haematology, 31(6), pp.”
BackgroundRedox Responsive Polymersomes for Enhanced Doxorubicin Delivery
Nehate, C., Nayal, A., & Koul, V. (2018) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.8b00238 · Cited by 43
In silico off-target profiling for enhanced drug safety assessment
Liu, J., Gui, Y., Rao, J., Sun, J., Wang, G., Ren, Q., Qu, N., Niu, B., Chen, Z., Sheng, X., et al. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.03.002 · Cited by 47
Livingston, C. A., Fabre, K. M., & Tagle, D. A. (2016) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2016.04.003 · Cited by 41
Human ex-vivo action potential model for pro-arrhythmia risk assessment
Page, G., Ratchada, P., Miron, Y., Steiner, G., Ghetti, A., Miller, P. E., Reynolds, J. A., Wang, K., Greiter-Wilke, A., Polonchuk, L., et al. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.05.016 · Cited by 41
“More than half of all development programs are terminated due to safety-related issues, not anticipated by the preclinical studies (Cook et al., 2014).”
Overcoming Translational Barriers in Acute Kidney Injury
Zuk, A., Palevsky, P. M., Fried, L. F., Harrell, F. E., Khan, S. S., McKay, D. B., Devey, L. R., Chawla, L. S., deCaestecker, M. P., Kaufman, J. S., et al. (2018) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.06820617 · Cited by 40
Oja, M., & Maran, U. (2018) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2018.07.014 · Cited by 46
Jones, G. N., Rooney, C., Griffin, N., Roudier, M. P., Young, L. A., Garcia-Trinidad, A., Hughes, G. D., Whiteaker, J. R., Wilson, Z., Odedra, R., et al. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0286-4 · Cited by 43
Is Diversity (Un-)Biased? Project Selection Decisions in Executive Committees
Oraiopoulos, N., & Kavadias, S. (2019) · Manufacturing & Service Operations Management · doi:10.1287/msom.2019.0782 · Cited by 42
Tang, X., Wang, Z., Hu, S., & Zhou, B. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14071313 · Cited by 39
“For example, 17% of drugs are halted at the preclinical stage due to cardiovascular toxicity [6].”
BackgroundHoque, A., Hossain, M. I., Ameen, S. S., Ang, C., Williamson, N. A., Ng, D. C. H., Chüeh, A. C., Roulston, C. L., & Cheng, H. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.02.009 · Cited by 43
“These determinants, which they referred to as five “Rs”, are right patients, right targets, right tissues, right safety and right commercial potential (Cook et al., 2014).”
BackgroundSynthesis and in vivo anticancer evaluation of poly(organo)phosphazene-based metallodrug conjugates
Hackl, C. M., Alte, B., Klose, M. H. M., Henke, H., Legina, M. S., Jakupec, M. A., Berger, W., Keppler, B. K., Brüggemann, O., Teasdale, I., et al. (2017) · Dalton Transactions · doi:10.1039/c7dt01767g · Cited by 40
Zloh, M., & Kirton, S. B. (2018) · Future Medicinal Chemistry · doi:10.4155/fmc-2017-0151 · Cited by 51
Matsuda, N., Odawara, A., Katoh, H., Okuyama, N., Yokoi, R., & Suzuki, I. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.02.117 · Cited by 40
“One of the major adverse events affecting the central nervous system observed during clinical trials is convulsions [3].”
BackgroundSjogren, A.-K. M., Breitholtz, K., Ahlberg, E., Milton, L., Forsgard, M., Persson, M., Stahl, S. H., Wilmer, M. J. G., & Hornberg, J. J. (2018) · Archives of Toxicology · doi:10.1007/s00204-018-2284-y · Cited by 42
Andersson, T. B. (2017) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12804 · Cited by 39
Doornbos, M. L. J., Cid, J. M., Haubrich, J., Nunes, A., van de Sande, J. W., Vermond, S. C., Mulder‐Krieger, T., Trabanco, A. A., Ahnaou, A., Drinkenburg, W. H. I. M., et al. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00669 · Cited by 41
Bajaj, P., Chung, G., Pye, K., Yukawa, T., Imanishi, A., Takai, Y., Brown, C., & Wagoner, M. P. (2020) · Toxicology · doi:10.1016/j.tox.2020.152535 · Cited by 39
Whichello, C. L., Bywall, K. S., Mauer, J., Stephen, W., Cleemput, I., Pinto, C. A., van Overbeeke, E., Huys, I., de Bekker-Grob, E. W., Hermann, R. P., et al. (2020) · Health Policy · doi:10.1016/j.healthpol.2020.07.007 · Cited by 44
Lee, J., Fernández‐Cadenas, I., & Lindgren, A. G. (2021) · Stroke · doi:10.1161/strokeaha.121.032622 · Cited by 44
Role of receptor occupancy assays by flow cytometry in drug development
Stewart, J. J., Green, C. L., Jones, N., Liang, M., Xu, Y., Wilkins, D. E. C., Moulard, M., Czechowska, K., Lanham, D., McCloskey, T. W., et al. (2015) · Cytometry Part B Clinical Cytometry · doi:10.1002/cyto.b.21355 · Cited by 38
Tissue chips to aid drug development and modeling for rare diseases
Low, L. A., & Tagle, D. A. (2016) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2016.1244479 · Cited by 38
Burt, T., Button, K. S., Thom, H. H. Z., Noveck, R. J., & Munafo, M. R. (2017) · Clinical and Translational Science · doi:10.1111/cts.12478 · Cited by 46
High-throughput flow cytometry for drug discovery: principles, applications, and case studies
Ding, M., Kaspersson, K., Murray, D., & Bardelle, C. (2017) · Drug Discovery Today · doi:10.1016/j.drudis.2017.09.005 · Cited by 38
Drugging DNA Damage Repair Pathways for Trinucleotide Repeat Expansion Diseases
Benn, C., Gibson, K. R., & Reynolds, D. S. (2020) · Journal of Huntington s Disease · doi:10.3233/jhd-200421 · Cited by 39
“We will focus on a set of important determinants identified in a retrospective analysis by Astra Zeneca which were echoed as critical by other large pharmaceutical companies such as Pfizer [24, 25].”
BackgroundInfluentialModels of Idiosyncratic Drug-Induced Liver Injury
Yokoi, T., & Oda, S. (2021) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-030220-015007 · Cited by 38
In Vitro Cancer Models: A Closer Look at Limitations on Translation
Antunes, N., Kundu, B., Kundu, S. C., Reis, R. L., & Correlo, V. M. (2022) · Bioengineering · doi:10.3390/bioengineering9040166 · Cited by 45
Compound Absorption in Polymer Devices Impairs the Translatability of Preclinical Safety Assessments
Kemas, A. M., Shafagh, R. Z., Taebnia, N., Michel, M., Preiss, L. C., Hofmann, U., & Lauschke, V. M. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202303561 · Cited by 45
Antiviral drug discovery and development: challenges and future directions
Du, S., Hu, X., Li, P., Xu, S., Kim, M., Liu, X., & Zhan, P. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02539-7 · Cited by 51
Increasing the delivery of next generation therapeutics from high throughput screening libraries
Wigglesworth, M. J., Murray, D. C., Blackett, C., Kossenjans, M., & Nissink, J. W. M. (2015) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2015.04.006 · Cited by 38
Yamagata, T., Zanelli, U., Gallemann, D., Perrin, D., Dolgos, H., & Petersson, C. (2016) · Xenobiotica · doi:10.1080/00498254.2016.1222639 · Cited by 39
“The prediction of human clearance is a central part of human dose predictions which was recently highlighted in several cooperate drug discovery strategies (Cook et al., 2014; Dolgos et al., 2016).”
BackgroundComplementary Approaches to Existing Target Based Drug Discovery for Identifying Novel Drug Targets
Vasaikar, S. V., Bhatia, P., Bhatia, P. G., & Yaiw, K.-C. (2016) · Biomedicines · doi:10.3390/biomedicines4040027 · Cited by 38
“AstraZeneca seems to establish a framework based on specific determinants like the right target, the right patient, the right tissue, the right safety and the right commercial potential [66].”
BackgroundModel selection and averaging of nonlinear mixed-effect models for robust phase III dose selection
Aoki, Y., Röshammar, D., Hamrén, B., & Hooker, A. C. (2017) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-017-9550-0 · Cited by 43
“Dosing information was not provided; however, as there were no statistically significant differences between the placebo group and the lowest dose group as described in [13], in this paper we refer this dataset as a ‘‘placebo’’ dataset.”
MethodKalaria, D. R., Parker, K., Reynolds, G., & Laru, J. (2020) · Drug Discovery Today · doi:10.1016/j.drudis.2019.12.012 · Cited by 41
Current and Future Challenges in Modern Drug Discovery
Tautermann, C. S. (2020) · Methods in molecular biology · doi:10.1007/978-1-0716-0282-9_1 · Cited by 50
Jun, G. R., You, Y., Zhu, C., Meng, G., Chung, J., Panitch, R., Hu, J., Xia, W., The Alzheimer's Disease Genetics Consortium, Bennett, D. A., et al. (2022) · Alzheimer's & Dementia · doi:10.1002/alz.12607 · Cited by 38
Beck, T., Rowlands, T., Shorter, T., & Brookes, A. J. (2022) · Nucleic Acids Research · doi:10.1093/nar/gkac1017 · Cited by 42
“Additionally, reviews have shown that efficacy in drug development can be improved by targeting GWAS disease risk genes (2,3).”
BackgroundGardiner, L.-J., Carrieri, A. P., Bingham, K., Macluskie, G., Bunton, D., McNeil, M., & Pyzer-Knapp, E. O. (2022) · PLOS ONE · doi:10.1371/journal.pone.0263248 · Cited by 36
Alternative splicing in lung influences COVID-19 severity and respiratory diseases
Nakanishi, T., Willett, J., Farjoun, Y., Allen, R. J., Guillén‐Guío, B., Adra, D., Zhou, S., & Richards, J. B. (2023) · Nature Communications · doi:10.1038/s41467-023-41912-4 · Cited by 35
Heining, P., & Ruysschaert, T. (2015) · Toxicologic Pathology · doi:10.1177/0192623315610823 · Cited by 56
“It is obvious that there is still some room for improvement in the predictivity of animal models related to safety issues caused by pharmaceutical development candidates in patients (Cook et al. 2014).”
BackgroundMao, F., Kong, Q., Wei Min, N. I., Xu, X., Ling, D., Lu, Z., & Li, J. (2016) · ChemistryOpen · doi:10.1002/open.201600015 · Cited by 44
Hurdles in Basic Science Translation
Perry, C. J., & Lawrence, A. J. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00478 · Cited by 39
“This can be partly attributed to a business-oriented culture found in research carried out by pharmaceutical companies (Cook et al., 2014); however, the problem is clearly not isolated to research within the private sector.”
BackgroundWeb-Based Tools for Polypharmacology Prediction
Awale, M., & Reymond, J. (2018) · Methods in molecular biology · doi:10.1007/978-1-4939-8891-4_15 · Cited by 38
Empowering phase II clinical trials to reduce phase III failures
Martini, D. D. (2019) · Pharmaceutical Statistics · doi:10.1002/pst.1980 · Cited by 40
Designing small molecules for therapeutic success: A contemporary perspective
Maurer, T. S., Edwards, M. P., Hepworth, D., Verhoest, P. R., & Allerton, C. M. N. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.09.017 · Cited by 42
Ramya, S., Loganathan, T., Chandran, M., Priyanka, R., Kavipriya, K., Pushpalatha, G. G. L., Devaraj, A., Ramanathan, L., Jayakumararaj, R., & Saluja, V. (2022) · Journal of Drug Delivery and Therapeutics · doi:10.22270/jddt.v12i2-s.5280 · Cited by 36
“Journal of Drug Delivery and Therapeutics 2021; 11(4):60-5.”
BackgroundRetinal ganglion cell-specific genetic regulation in primary open-angle glaucoma
Daniszewski, M., Senabouth, A., Liang, H. H., Han, X., Lidgerwood, G. E., Hernández, D., Sivakumaran, P., Clarke, J. E., Lim, S. Y., Lees, J. G., et al. (2022) · Cell Genomics · doi:10.1016/j.xgen.2022.100142 · Cited by 39
Application of three-dimensional (3D) bioprinting in anti-cancer therapy
Wu, B., Wu, Z. Q., Hou, Y.-Y., Fang, Z.-X., Deng, Y., Wu, H.-T., & Liu, J. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e20475 · Cited by 44
“However, the complexity and diversity of the TME or accurately predict drug response in such models are limited, which leads to a lack of efficacy in clinical trials [5,15,16].”
BackgroundEwart, L., Apostolou, A., Briggs, S. A., Carman, C. V., Chaff, J. T., Heng, A. R., Jadalannagari, S., Janardhanan, J., Jang, K.-J., Joshipura, S. R., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.12.14.472674 · Cited by 36
“membrane (4) within the upper parenchymal channel (1), while human liver sinusoidal endothelial cells (7), Kupffer cells (6), and stellate cells (5) are cultured on the opposite side of the membrane in the lower vascular channel (8).”
BackgroundPromising Targets for the Treatment of Neurodegenerative Diseases
Budd Haeberlein, S., & Harris, T. (2015) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.195 · Cited by 35
Medigeshi, G. R., Kumar, R., Dhamija, E., Agrawal, T., & Kar, M. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01367-16 · Cited by 40
“In cases where the drug has been proven to be safe for human use for other conditions, this process helps to bring the drug to human use faster than a new candidate drug, which, according to industry estimates, takes 12 to 15 years from discovery to therapeutic use (5, 6).”
Updating molecular properties during early drug discovery
Caron, G., & Ermondi, G. (2016) · Drug Discovery Today · doi:10.1016/j.drudis.2016.11.017 · Cited by 35
Bile salt enhancers for inhalation: Correlation between in vitro and in vivo lung effects
Sørli, J. B., Sivars, K. B., Silva, E. D., Hougaard, K. S., Koponen, I. K., Zuo, Y. Y., Weydahl, I. E. K., Åberg, P. M., & Fransson, R. (2018) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2018.08.031 · Cited by 38
“Analysis of the AstraZeneca drug portfolio between 2005 and 2010 showed that safety attrition of inhaled candidate drugs due to toxicity to the respiratory system accounted for about 30% of the project closures related to adverse respiratory effects (Cook et al., 2014).”
BackgroundAccelerated drug discovery by rapid candidate drug identification
Bergström, F., & Lindmark, B. (2019) · Drug Discovery Today · doi:10.1016/j.drudis.2019.03.026 · Cited by 37
Margiotta‐Casaluci, L., Owen, S. F., Rand‐Weaver, M., & Winter, M. J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00893 · Cited by 36
Project Selection and Success: Insights from the Drug Discovery Process
Markou, P., Kavadias, S., & Oraiopoulos, N. (2018) · Management Science · doi:10.1287/mnsc.2022.4642 · Cited by 38
Inhibition of MERTK reduces organ fibrosis in mouse models of fibrotic disease
Pan, Z., Sharkway, R. E., Bayoumi, A., Metwally, M., Gloss, B., Brink, R. A., Lu, D. B., Liddle, C., Alqahtani, S. A., Yu, J. Q., et al. (2024) · Science Translational Medicine · doi:10.1126/scitranslmed.adj0133 · Cited by 41
“Validation of genomic approaches has come from analyses of pharmaceutical pipelines ( 6 , 7 ) that demonstrate that drug targets for which a genetic link to disease is evident have more than double the chance of reaching the clinic than targets that have no such link ( 6 , 7 ).”
BackgroundHolmes, A. M., Charlton, A., Derby, B., Ewart, L. C., Scott, A., & Shu, W. (2017) · Biofabrication · doi:10.1088/1758-5090/aa7bbd · Cited by 40
“But a substantial proportion of this failure can be attributed to the lack of safety or efficacy, suggesting the preclinical models used to assess these poorly translate to the clinic [22].”
BackgroundVeyres, N., Hamadjida, A., & Huot, P. (2018) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.117.247171 · Cited by 40
“…to conduct behavioral pharmacologic research (Porras et al., 2012); also, there have been several failures of high-profile drugs in clinical trials (Cook et al., 2014; Bespalov et al., 2016), emphasizing the need to use the best animal model possible in preclinical settings to maximize chances of…”
BackgroundA simple model to solve a complex drug toxicity problem
Dixit, V. A. (2018) · Toxicology Research · doi:10.1039/c8tx00261d · Cited by 40
Intracellular concentrations determine the cytotoxicity of adefovir, cidofovir and tenofovir
Zhang, X., Wang, R., Piotrowski, M. A., Zhang, H., & Leach, K. L. (2014) · Toxicology in Vitro · doi:10.1016/j.tiv.2014.10.019 · Cited by 36
Pfeiffer, E. R., Vega, R., McDonough, P. M., Price, J. H., & Whittaker, R. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.04.007 · Cited by 35
Helmlinger, G., Al-Huniti, N., Aksenov, S., Peskov, K., Hallow, K. M., Chu, L., Boulton, D., Eriksson, U., Hamrén, B., Lambert, C., et al. (2017) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2017.05.028 · Cited by 33
Development of a human genetics-guided priority score for 19,365 genes and 399 drug indications
Duffy, Á., Petrazzini, B. O., Stein, D. F., Park, J. K., Forrest, I. S., Gibson, K., Vy, H. M. T., Chen, R. K., Márquez‐Luna, C., Mort, M. E., et al. (2024) · Nature Genetics · doi:10.1038/s41588-023-01609-2 · Cited by 44
“Several studies have shown that drug indications with human genetic support are more likely to advance through clinical trials and be approved 2,4,5 .”
Carlo, A. D., Ronchi, D., Piastra, M., Tosca, E. M., & Magni, P. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060776 · Cited by 40
“Cook et al. [2] comprehensively reviewed the results of AstraZeneca small-molecule drug projects from 2005 to 2010 and found that undesirable absorption, distribution, metabolism, excretion and toxicity (ADMET) properties are a leading cause of failure in the clinical phase of drug development.”
BackgroundRosenthal, K. S., Mikecz, K., Steiner, H. L., Glant, T. T., Finnegan, A., Carambula, R. E., & Zimmerman, D. H. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.1026330 · Cited by 33
“and appropriate dosing may be difficult to establish without performing clinical (human) trials [124].”
BackgroundStåhl, M., & Baier, S. (2015) · ChemMedChem · doi:10.1002/cmdc.201500091 · Cited by 31
Abi‐Gerges, N., Pointon, A., Oldman, K. L., Brown, M. R., Pilling, M. A., Sefton, C. E., Garside, H., & Pollard, C. E. (2016) · Journal of Pharmacological and Toxicological Methods · doi:10.1016/j.vascn.2016.09.001 · Cited by 36
Harnessing the Versatility of Optical Biosensors for Target-Based Small-Molecule Drug Discovery
Kaminski, T. P., Gunnarsson, A., & Geschwindner, S. (2016) · ACS Sensors · doi:10.1021/acssensors.6b00735 · Cited by 33
Hefti, F. F. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.04.024 · Cited by 33
Mamoshina, P., Bueno‐Orovio, A., & Rodríguez, B. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00639 · Cited by 37
“Drug cardiotoxicity significantly limits the application of numerous therapies, and also slows down the drug research and development process (Cook et al., 2014; Onakpoya et al., 2016).”
BackgroundInfluentialNieskens, T. T. G., Magnusson, O., Andersson, P. U., Söderberg, M. P., Persson, M., & Sjogren, A.-K. M. (2021) · Archives of Toxicology · doi:10.1007/s00204-021-03062-8 · Cited by 33
How does basic research improve innovation performance in the world’s major pharmaceutical firms?
Leten, B., Kelchtermans, S., & Belderbos, R. (2021) · Industry and Innovation · doi:10.1080/13662716.2021.1997723 · Cited by 42
Multiomics in atherosclerotic cardiovascular disease
Nordestgaard, L. T., Wolford, B. N., de Gonzalo‐Calvo, D., Sopić, M., Devaux, Y., Matic, L. P., Wettinger, S. B., Schmid, J. A., Amigó, N., Masana, L., et al. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120414 · Cited by 41
Prina‐Mello, A., Jain, N., Liu, B., Kilpatrick, J. I., Tutty, M. A., Bell, A. P., Jarvis, S., Volkov, Y., & Movia, D. (2017) · Tissue and Cell · doi:10.1016/j.tice.2017.11.003 · Cited by 34
Nehate, C., Raynold, A. A. M., Haridas, V., & Koul, V. (2018) · Biomacromolecules · doi:10.1021/acs.biomac.8b00178 · Cited by 33
Fang, H., Chen, L., & Knight, J. C. (2019) · The Lancet Rheumatology · doi:10.1016/s2665-9913(19)30134-1 · Cited by 32
Genomics-guided pre-clinical development of cancer therapies
Francies, H. E., McDermott, U., & Garnett, M. J. (2020) · Nature Cancer · doi:10.1038/s43018-020-0067-x · Cited by 34
Urinary miRNA Biomarkers of Drug-Induced Kidney Injury and Their Site Specificity Within the Nephron
Chorley, B. N., Ellinger-Ziegelbauer, H. C., Tackett, M., Simutis, F., Harrill, A. H., McDuffie, J. E., Atabakhsh, E., Nassirpour, R., Whiteley, L. O., Léonard, J., et al. (2020) · Toxicological Sciences · doi:10.1093/toxsci/kfaa181 · Cited by 32
Agreement between two large pan-cancer CRISPR-Cas9 gene dependency datasetsPreprint
Dempster, J. M., Pacini, C., Pantel, S., Behan, F. M., Green, T., Krill-Burger, J. M., Beaver, C., Younger, S. T., Zhivich, V., Najgebauer, H., et al. (2019) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/604447 · Cited by 32
Evaluating the Past, Present, and Future of Regenerative Medicine: A Global View
Ronfard, V., Vertès, A. A., May, M., Anne, D., Dyke, M. E. V., & Bayon, Y. (2016) · Tissue Engineering Part B Reviews · doi:10.1089/ten.teb.2016.0291 · Cited by 35
A model-based assay design to reproduce in vivo patterns of acute drug-induced toxicity
Kuepfer, L., Clayton, O., Thiel, C., Cordes, H., Nudischer, R., Blank, L. M., Baier, V., Heymans, S. R. B., Caiment, F., Roth, A. B., et al. (2017) · Archives of Toxicology · doi:10.1007/s00204-017-2041-7 · Cited by 35
“of the cardiovascular system, the liver, the central nervous system and skeletal muscle (Cook et al. 2014).”
BackgroundLucas, A. T., Robinson, R., Schorzman, A. N., Piscitelli, J. A., Razo, J. F., & Zamboni, W. C. (2019) · Antibodies · doi:10.3390/antib8010003 · Cited by 35
“High-throughput methods to increase PK/PD analyses would be advantageous, especially as it has been implied that roughly 15% of phase I studies fail due to an unfavorable pharmacologic disposition [274].”
BackgroundFrom Target Identification to Drug Development in Space: Using the Microgravity Assist
Braddock, M. (2019) · Current Drug Discovery Technologies · doi:10.2174/1570163816666190112150014 · Cited by 36
Metadata
- Authors
- Cook, D., Brown, D., Alexander, R., March, R., Morgan, P., Satterthwaite, G., & Pangalos, M. N.
- Affiliations
- AstraZeneca (United Kingdom) (GB)
- Corresponding author
- Pangalos, Menelas N.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2014-05-16
- Volume
- 13
- Issue
- 6
- Pages
- 419-431
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1967105697
- Cited by
- 1,344
- References
- 75
- Citations by year
- 2026: 90 · 2025: 92 · 2024: 104 · 2023: 110 · 2022: 99 · 2021: 123 · 2020: 118 · 2019: 125 · 2018: 131 · 2017: 115 · 2016: 124 · 2015: 92 · 2014: 20
- FWCI
- 33.03
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Keywords
- AstraZeneca, drug development pipeline, small molecule drug development, R&D productivity, project success factors, target selection, patient selection, tissue selection, drug safety, business potential, organizational culture, pharmaceutical industry
- MeSH terms
- Animals, Clinical Trials as Topic, Decision Making, Organizational, Drug Industry, Drug Evaluation, Preclinical, Humans, Research Support as Topic, Technology, Pharmaceutical, Drug Design, Organizational Culture, Drugs, Investigational, Models, Organizational, Efficiency, Organizational, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.